Science's new study provides critical information about glioma size and growth rate

A study led by Mount Sinai Hospital in Toronto and the Mayo Clinic Comprehensive Cancer Center has uncovered an important new clue
to the prevention and treatment of glioma.
The study, published in the journal Science, provides a rare window
into the biological changes behind glioma development.

The researchers found that animal models carrying the germline variant rs55705857 gene developed gliomas more frequently than animal models without this variant and took only half the time
.
In addition to brain tumors, the findings have also been linked to
other cancers and diseases.

"While we have a great deal of understanding of the biological function of germline-altered germline alterations in genes that encode proteins, we know very little
about the biological functions of germline-altered germline changes outside of genes encoding proteins.
" To some extent, these germline changes interact with other mutations in the cell, accelerating tumor formation," said Robert Jenkins of the Mayo Clinic in Rochester, "Based on this new understanding of its mechanism of action, future research could lead to new and specific treatments for the rs55705857 mutation
.
" ”

This study provides new knowledge that can help clinicians determine if a patient has a glioma
before surgery.

"We expected rs55705857 to accelerate the development of low-grade gliomas, but we were surprised by the magnitude of this acceleration," said
lead author Dr.
Daniel Schramek.

In addition to the genes associated with the occurrence of cancer and other diseases, Schramek said, there are many alterations, possibly thousands, but only a tiny minority of people understand their mechanisms of
action.

This study suggests that with the help of modern molecular/cell biology tools, it is possible to decipher much of the mechanism
of action of this change.